Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Silica-Based Carriers for Drug Delivery
share announcement

Silica-Based Carriers for Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 7982

Special Issue Editors

Dr. Marlus Chorilli

E-Mail Website
Guest Editor
Department of Drugs and Medicines, São Paulo State University—UNESP, Rodovia Araraquara Jaú, Km 1, Araraquara 14800-903, SP, Brazil
Interests: lipid-based carriers; drug delivery systems; in vivo assays; clinical assays
Special Issues, Collections and Topics in MDPI journals
Dr. Rafael Miguel Sábio

E-Mail Website
Guest Editor
School of Pharmaceutical Sciences, São Paulo State University (UNESP), Rodovia Araraquara-Jaú, Km 01, Araraquara 14800-903, SP, Brazil
Interests: silica-based carriers; mesoporous silica; inorganic nanoparticles; organic nanoparticles; biopolymers; surface functionalization; drug delivery systems; cancer

Special Issue Information

Dear Colleagues,

The design of silica-based carriers as drug delivery systems has grown exponentially due to their remarkable adjustable characteristics such as high surface area, chemical and physical stabilities, high loading and release capacities, tunable particle and pore structures, as well as good biocompatibility, biodegradability and easy clearance. However, before fabricating a smart and specific silica-based platforms is extremely relevant to know and well-understand the main exposure routes that exploit their qualities, such as intravenous, subcutaneous, intramuscular, intratumoral, ophthalmic, pulmonary, nasal, dermal, and oral administrations, and so forth. Taking into account the relevance and timely contribution of silica nano and microsystems as smart carriers for efficient drug delivery via several routes of administration, we would like to invite you to participate by proposing short communication, original and review papers to this issue: “Silica-based carriers for drug delivery”. This special edition of Pharmaceutics deals with new strategies to design and to apply any type of silica-based carriers as effective drug delivery systems.

Prof. Dr. Marlus Chorilli
Dr. Rafael Miguel Sábio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • silica-based carriers
  • drug delivery systems
  • in vivo assays

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2920 KiB  
Article
Mesoporous Organosilica Nanoparticles to Fight Intracellular Staphylococcal Aureus Infections in Macrophages
by Manasi Jambhrunkar, Sajedeh Maghrebi, Divya Doddakyathanahalli, Anthony Wignall, Clive A. Prestidge and Kristen E. Bremmell
Pharmaceutics 2023, 15(4), 1037; https://doi.org/10.3390/pharmaceutics15041037 - 23 Mar 2023
Cited by 2 | Viewed by 1340
Abstract
Intracellular bacteria are inaccessible and highly tolerant to antibiotics, hence are a major contributor to the global challenge of antibiotic resistance and recalcitrant clinical infections. This, in tandem with stagnant antibacterial discovery, highlights an unmet need for new delivery technologies to treat intracellular [...] Read more.
Intracellular bacteria are inaccessible and highly tolerant to antibiotics, hence are a major contributor to the global challenge of antibiotic resistance and recalcitrant clinical infections. This, in tandem with stagnant antibacterial discovery, highlights an unmet need for new delivery technologies to treat intracellular infections more effectively. Here, we compare the uptake, delivery, and efficacy of rifampicin (Rif)-loaded mesoporous silica nanoparticles (MSN) and organo-modified (ethylene-bridged) MSN (MON) as an antibiotic treatment against small colony variants (SCV) Staphylococcus aureus (SA) in murine macrophages (RAW 264.7). Macrophage uptake of MON was five-fold that of equivalent sized MSN and without significant cytotoxicity on human embryonic kidney cells (HEK 293T) or RAW 264.7 cells. MON also facilitated increased Rif loading with sustained release, and seven-fold increased Rif delivery to infected macrophages. The combined effects of increased uptake and intracellular delivery of Rif by MON reduced the colony forming units of intracellular SCV-SA 28 times and 65 times compared to MSN-Rif and non-encapsulated Rif, respectively (at a dose of 5 µg/mL). Conclusively, the organic framework of MON offers significant advantages and opportunities over MSN for the treatment of intracellular infections. Full article
(This article belongs to the Special Issue Silica-Based Carriers for Drug Delivery)
►▼ Show Figures

Graphical abstract

21 pages, 4251 KiB  
Article
Enhanced Solubility and Biological Activity of Dexibuprofen-Loaded Silica-Based Ternary Solid Dispersions
by Muhammad Asim, Marriam Nazir, Zunera Chauhdary, Muhammad Irfan, Syed Haroon Khalid, Sajid Asghar, Usra, Raed I. Felimban, Mohammed A Majrashi, Mohannad S. Hazzazi, Mohammed Alissa, Safa H Qahl, Ghulam Hussain, Azhar Rasul, Shahzad Ali Shahid Chatha and Ikram Ullah Khan
Pharmaceutics 2023, 15(2), 399; https://doi.org/10.3390/pharmaceutics15020399 - 24 Jan 2023
Cited by 1 | Viewed by 1571
Abstract
The current study was designed to formulate ternary solid dispersions (TSDs) of dexibuprofen (Dex) by solvent evaporation to augment the solubility and dissolution profile, in turn providing gastric protection and effective anti-inflammatory activity. Initially, nine formulations (S1 to S9) of binary solid dispersions [...] Read more.
The current study was designed to formulate ternary solid dispersions (TSDs) of dexibuprofen (Dex) by solvent evaporation to augment the solubility and dissolution profile, in turn providing gastric protection and effective anti-inflammatory activity. Initially, nine formulations (S1 to S9) of binary solid dispersions (BSDs) were developed. Formulation S1 comprising a 1:1 weight ratio of Dex and Syloid 244FP® was chosen as the optimum BSD formulation due to its better solubility profile. Afterward, 20 TSD formulations were developed using the optimum BSD. The formulation containing Syloid 244FP® with 40% Gelucire 48/16® (S18) and Poloxamer 188® (S23) successfully enhanced the solubility by 28.23 and 38.02 times, respectively, in pH 6.8, while dissolution was increased by 1.99- and 2.01-fold during the first 5 min as compared to pure drug. The in vivo gastroprotective study in rats suggested that the average gastric lesion index was in the order of pure Dex (8.33 ± 2.02) > S1 (7 ± 1.32) > S18 (2.17 ± 1.61) > S23 (1.83 ± 1.04) > control (0). The in vivo anti-inflammatory study in rats revealed that the percentage inhibition of swelling was in the order of S23 (71.47 ± 2.16) > S18 (64.8 ± 3.79) > S1 (54.14 ± 6.78) > pure drug (18.43 ± 2.21) > control (1.18 ± 0.64) after 6 h. ELISA results further confirmed the anti-inflammatory potential of the developed formulation, where low levels of IL-6 and TNF alpha were reported for animals treated with S23. Therefore, S23 could be considered an effective formulation that not only enhanced the solubility and bioavailability but also reduced the gastric irritation of Dex. Full article
(This article belongs to the Special Issue Silica-Based Carriers for Drug Delivery)
►▼ Show Figures

Figure 1

11 pages, 1070 KiB  
Article
Mesoporous Silica Particles Functionalized with Newly Extracted Fish Oil (Omeg@Silica) Reducing IL-8 Counteract Cell Migration in NSCLC Cell Lines
by Claudia D’Anna, Caterina Di Sano, Serena Di Vincenzo, Simona Taverna, Giuseppe Cammarata, Antonino Scurria, Mario Pagliaro, Rosaria Ciriminna and Elisabetta Pace
Pharmaceutics 2022, 14(10), 2079; https://doi.org/10.3390/pharmaceutics14102079 - 29 Sep 2022
Cited by 3 | Viewed by 1444
Abstract
Lung cancer is one of the leading forms of cancer in developed countries. Interleukin-8 (IL-8), a pro-inflammatory cytokine, exerts relevant effects in cancer growth and progression, including angiogenesis and metastasis in lung cancer. Mesoporous silica particles, functionalized with newly extracted fish oil (Omeg@Silica), [...] Read more.
Lung cancer is one of the leading forms of cancer in developed countries. Interleukin-8 (IL-8), a pro-inflammatory cytokine, exerts relevant effects in cancer growth and progression, including angiogenesis and metastasis in lung cancer. Mesoporous silica particles, functionalized with newly extracted fish oil (Omeg@Silica), are more effective than the fish oil alone in anti-proliferative and pro-apoptotic effects in non-small cell lung cancer (NSCLC) cell lines. The mechanisms that explain this efficacy are not yet understood. The aim of the present study is therefore to decipher the anti-cancer effects of a formulation of Omeg@Silica in aqueous ethanol (FOS) in adenocarcinoma (A549) and muco-epidermoid (NCI-H292) lung cancer cells, evaluating cell migration, as well as IL-8, NF-κB, and miRNA-21 expression. Results show that in both cell lines, FOS was more efficient than oil alone, in decreasing cell migration and IL-8 gene expression. FOS reduced IL-8 protein release in both cell lines, but this effect was only stronger than the oil alone in A549. In A549, FOS was able to reduce miRNA-21 and transcription factor NF-κB nuclear expression. Taken together, these data support the potential use of the Omeg@Silica as an add-on therapy for NSCLC. Dedicated studies which prove clinical efficacy are needed. Full article
(This article belongs to the Special Issue Silica-Based Carriers for Drug Delivery)
►▼ Show Figures

Figure 1

19 pages, 3444 KiB  
Article
Curcumin-Loaded Mesoporous Silica Nanoparticles Dispersed in Thermo-Responsive Hydrogel as Potential Alzheimer Disease Therapy
by Tais de Cassia Ribeiro, Rafael Miguel Sábio, Marcela Tavares Luiz, Lucas Canto de Souza, Bruno Fonseca-Santos, Luis Carlos Cides da Silva, Márcia Carvalho de Abreu Fantini, Cleopatra da Silva Planeta and Marlus Chorilli
Pharmaceutics 2022, 14(9), 1976; https://doi.org/10.3390/pharmaceutics14091976 - 19 Sep 2022
Cited by 22 | Viewed by 3082
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive and behavioral impairment. Curcumin-loaded mesoporous silica nanoparticles (MSN-CCM) can overcome the drawbacks related to the free curcumin (CCM) clinical application, such as water insolubility and low bioavailability, besides acting over the main causes [...] Read more.
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive and behavioral impairment. Curcumin-loaded mesoporous silica nanoparticles (MSN-CCM) can overcome the drawbacks related to the free curcumin (CCM) clinical application, such as water insolubility and low bioavailability, besides acting over the main causes associated to AD. A thermo-responsive hydrogel is an interesting approach for facilitating the administration of the nanosystem via a nasal route, as well as for overcoming mucociliary clearance mechanisms. In light of this, MSN-CCM were dispersed in the hydrogel and evaluated through in vitro and in vivo assays. The MSNs and MSN-CCM were successfully characterized by physicochemical analysis and a high value of the CCM encapsulation efficiency (EE%, 87.70 ± 0.05) was achieved. The designed thermo-responsive hydrogel (HG) was characterized by rheology, texture profile analysis, and ex vivo mucoadhesion, showing excellent mechanical and mucoadhesive properties. Ex vivo permeation studies of MSN-CCM and HG@MSN-CCM showed high permeation values (12.46 ± 1.08 and 28.40 ± 1.88 μg cm−2 of CCM, respectively) in porcine nasal mucosa. In vivo studies performed in a streptozotocin-induced AD model confirmed that HG@MSN-CCM reverted the cognitive deficit in mice, acting as a potential formulation in the treatment of AD. Full article
(This article belongs to the Special Issue Silica-Based Carriers for Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop